| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.0088 | 0.9 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | 0.0094 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |